Defective GABAergic Neurotransmission and Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a Mouse Model of Fragile X Syndrome
Open accessAbstract
Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by variable cognitive impairment and behavioral disturbances such as exaggerated fear, anxiety and gaze avoidance. Consistent with this, findings from human brain imaging studies suggest dysfunction of the amygdala. Underlying alterations in amygdala synaptic function in the Fmr1 knock-out (KO) mouse model of FXS, however, remain largely unexplored. Utilizing a combination of approaches, we uncover profound alterations in inhibitory neurotransmission in the amygdala of Fmr1 KO mice. We demonstrate a dramatic reduction in the frequency and amplitude of phasic IPSCs, tonic inhibitory currents, as well as in the number of inhibitory synapses in Fmr1 KO mice. Furthermore, we observe significant alterations in GABA availability, both intracellularly and at the synaptic cleft. Together, these findings identify abnormalities in basal and action potential-dependent inhibitory neurotransmission. Additionally, we reveal a significant neuronal hyperexcitability in principal neurons of the amygdala in Fmr1 KO mice, which is strikingly rescued by pharmacological augmentation of tonic inhibitory tone using the GABA agonist gaboxadol (THIP). Thus, our study reveals relevant inhibitory synaptic abnormalities in the amygdala in the Fmr1 KO brain and supports the notion that pharmacological approaches targeting the GABAergic system may be a viable therapeutic approach toward correcting amygdala-based symptoms in FXS.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pharmacological approaches targeting the GABAergic system have been successfully exploited to correct amygdala-based symptoms in fragile X syndrome.
“Pharmacological approaches targeting the GABAergic system have been successfully exploited to correct amygdala-based symptoms in FXS (114).”
From Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics (2012) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 62 · Cited by 309
- Authors
- Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G., & Huntsman, M. M.
- Affiliations
- Children's National (US)
- Kennedy Krieger Institute (US)
- Venue
- Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-07-21
- Volume
- 30
- Issue
- 29
- Pages
- 9929-9938
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC2948869
- OpenAlex
- W2078544102
- Cited by
- 309
- References
- 62
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 9 · 2023: 12 · 2022: 22 · 2021: 16 · 2020: 17 · 2019: 14 · 2018: 15 · 2017: 25 · 2016: 22 · 2015: 24 · 2014: 29 · 2013: 29 · 2012: 28
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (181393)
- National Institute on Drug Abuse (DA020140, R01DA020140)
- National Institute of Neurological Disorders and Stroke (NS-053719, R01NS053719, R56NS053719)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD40677, P30HD040677)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
- Keywords
- fragile X syndrome, Fmr1 knockout mice, amygdala, GABAergic neurotransmission, synaptic inhibition, neuronal hyperexcitability, inhibitory postsynaptic currents, gaboxadol, THIP, FMRP, anxiety, fear, pharmacological rescue
- MeSH terms
- Amygdala, Animals, Disease Models, Animal, Evoked Potentials, Fragile X Syndrome, gamma-Aminobutyric Acid, Glutamate Decarboxylase, Interneurons, Isoxazoles, Male, Neural Inhibition, Synaptic Transmission, Neurons, Mice, Knockout, Patch-Clamp Techniques, GABA Agonists, Mice, Fragile X Messenger Ribonucleoprotein 1, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review